Please assess the completion status of the following clinical trial:

Trial Title: Artemisinin Resistance in Bangladesh

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute symptomatic falciparum malaria infection as determined by malaria smear with a parasite density of 1,000 to 100,000 asexual parasites/uL as determined on the screening smear with fever (defined as ≥37.5C), or reported history of fever within the last 48 hours.~2. Age: 8-65 years old~3. All females between the age of 12 and 50 are required to have a negative human chorionic gonadotropin (hCG) pregnancy test (urine). All females of childbearing potential (not surgically sterile, or less than two years menopausal) are required to use an acceptable method of contraception throughout the study~4. Written informed consent obtained~5. Willing to stay under close medical supervision for the study duration of 42 days~6. Otherwise healthy outpatients~Exclusion Criteria:~1. Pregnant women, nursing mothers, or women of childbearing potential who do not use an acceptable method of contraception~2. Mixed malaria infection on admission by malaria smear~3. A previous history of intolerance or hypersensitivity to the study drugs or to drugs with similar chemical structures~4. Malaria drug therapy administered in the past 30 days by history~5. History of significant cardiovascular, liver or renal functional abnormality or any other clinically significant illness, which in the opinion of the investigator would place them at increased risk.~6. Symptoms of severe vomiting (no food or inability to take food during the previous 8 hours).~7. Signs or symptoms of severe malaria (as defined by WHO 2000)~8. Unable and/or unlikely to comprehend and/or follow the protocol

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AS 2mg/kg (Type: EXPERIMENTAL): Artesunate monotherapy 2mg/kg/day for 7 days
- AS 4mg/kg (Type: EXPERIMENTAL): Artesunate monotherapy 4mg/kg/day for 7 days
- QD Control (Type: ACTIVE_COMPARATOR): Quinine-doxycycline for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).